The prediction for efficacy of gemcitabine postoperative adjuvant chemotherapy in pancreatic cancer by the expression analysis of the metabolic enzymes and transporters using LC-MS/MS Quantitative Targeted Proteomics

The prediction for efficacy of gemcitabine postoperative adjuvant chemotherapy in pancreatic cancer by the expression analysis of the metabolic enzymes and transporters using LC-MS/MS Quantitative Targeted Proteomics - The prediction for the efficacy of gemcitabine postoperative adjuvant chemotherapy in pancreatic cancer using LC-MS/MS Quantitative Targeted Proteomics

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000006253

Enrollment

Registered

2011-09-01

Start date

2011-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients who administered curative resection(R0 and R1) for pancreatic cancer (invasive ductal carcinoma)

Exclusion criteria

Exclusion criteria: 1. patients who administered non-curative resection (R2) 2. pancreatic cancer expect for invasive ductal carcinoma

Design outcomes

Primary

Measure	Time frame
overall survival, progression free survival, expression level of metabolic enzymes and transporters	—

Countries

Japan

Contacts

Public ContactHideo Ohtsuka

Tohoku university Hepato-biliary pancreatic surgery

ohtsuka@surg1.med.tohoku.ac.jp

Outcome results